As of close of business last night, Alignment Healthcare Inc’s stock clocked out at $5.30, down -1.67% from its previous closing price of $5.39. In other words, the price has decreased by -$0.09 from its previous closing price. On the day, 802420 shares were traded.
Ratios:
To gain a deeper understanding of ALHC’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Underweight rating and assigned the stock a target price of $4.50.
On March 06, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $12 to $6.
On January 24, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $11.Stifel initiated its Buy rating on January 24, 2024, with a $11 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 14 ’23 when MARGOLIS JEFFREY H sold 1,200 shares for $8.46 per share. The transaction valued at 10,152 led to the insider holds 417,133 shares of the business.
MARGOLIS JEFFREY H sold 1,200 shares of ALHC for $9,600 on Dec 06 ’23. The Director now owns 418,333 shares after completing the transaction at $8.00 per share. On Nov 10 ’23, another insider, KONOWIECKI JOSEPH S, who serves as the Chairman of the Board of the company, sold 4,898 shares for $5.90 each. As a result, the insider received 28,898 and left with 1,188,221 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 1.02B and an Enterprise Value of 868.67M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.55 while its Price-to-Book (P/B) ratio in mrq is 6.38. Its current Enterprise Value per Revenue stands at 0.48 whereas that against EBITDA is -8.25.
Stock Price History:
Over the past 52 weeks, ALHC has reached a high of $9.20, while it has fallen to a 52-week low of $4.88. The 50-Day Moving Average of the stock is 6.96, while the 200-Day Moving Average is calculated to be 6.67.
Shares Statistics:
It appears that ALHC traded 771.03K shares on average per day over the past three months and 1.34M shares per day over the past ten days. A total of 188.95M shares are outstanding, with a floating share count of 94.82M. Insiders hold about 49.82% of the company’s shares, while institutions hold 43.06% stake in the company. Shares short for ALHC as of Feb 15, 2024 were 4.1M with a Short Ratio of 5.32, compared to 3.65M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.17% and a Short% of Float of 3.43%.
Earnings Estimates
As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.25, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.06 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.3 and -$0.75 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.46, with 11 analysts recommending between -$0.21 and -$0.59.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $596.42M. It ranges from a high estimate of $598.56M to a low estimate of $594.88M. As of the current estimate, Alignment Healthcare Inc’s year-ago sales were $439.15M, an estimated increase of 35.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $607.84M, an increase of 38.50% over than the figure of $35.80% in the same quarter last year. There is a high estimate of $620.26M for the next quarter, whereas the lowest estimate is $586.4M.
A total of 10 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $2.53B, while the lowest revenue estimate was $2.4B, resulting in an average revenue estimate of $2.41B. In the same quarter a year ago, actual revenue was $1.82B, up 32.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $2.9B in the next fiscal year. The high estimate is $3.04B and the low estimate is $2.75B. The average revenue growth estimate for next year is up 19.90% from the average revenue estimate for this year.
